Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030261 · ClinicalTrials.gov registry record · Phase 2
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase 2 study of Multiple Myeloma in Relapse, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT03030261: Active Phase 2 study of Multiple Myeloma in Relapse, sponsored by Washington University School of Medicine.
NCT03030261 is a Phase 2 study of Multiple Myeloma in Relapse that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 25 participants, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (50% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030261, a Phase 2 study of Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durability of responses which is essential to improving outcomes following second ASCT.
Primary Outcome
-Event-free survival (EFS) will be defined as time from ASCT to disease progression, relapse, or death, whichever occurs first. Patients who are removed from study therapy prior to any of these events occurring will be censored at the time of initiation of subsequent anti-myeloma treatment.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Elotuzumab
Study Locations (3)
Colorado
- Colorado Blood Cancer Institute (Sarah Cannon) - Denver
Missouri
- Washington University School of Medicine - St Louis
Ontario
- University Health Network - Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2027-09-26 |
| Phase | Phase 2 |
What the registry record for NCT03030261 still lists
NCT03030261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03030261 reports a single indexed study location in Colorado, Missouri, Ontario.
Frequently Asked Questions
What is clinical trial NCT03030261 about?
NCT03030261 is a clinical study titled "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma". Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is acti...
What is the current status of trial NCT03030261?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-11-22. Estimated completion is 2027-09-26.
What conditions does trial NCT03030261 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse.
What interventions are being tested in trial NCT03030261?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT03030261?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03030261 being conducted?
This trial has 3 study locations across Colorado, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03030261's enrollment target sits among peer trials
25 9th of 12 higher than 4 of 12 other Multiple Myeloma in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RECRUITING · Phase 2
-
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI